Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Melanoma

Hypoxia-inducible factor 1a (HIF1A; HIF1a); endothelial PAS domain protein 1 (EPAS1; HIF2A)

In vitro and mouse studies suggest inhibiting HIF1A or HIF2A could prevent metastatic melanoma. In metastatic human melanoma cell lines, hypoxia induced HIF1A and HIF2A expression and increased invasiveness compared with normal oxygen conditions. In these cell lines, small interfering RNA against HIF1A or HIF2A decreased invasiveness compared with scrambled siRNA. In a mouse xenograft model for melanoma, a deficiency in Hif1a or Hif2a led to decreased lymph node metastases compared with those seen in wild-type controls. Next steps could include inhibiting HIF1A and/or HIF2A in xenograft models for established metastatic melanoma.
Calando Pharmaceuticals Inc. and Cerulean Pharma Inc. have CRLX101 (formerly IT-101), a dual inhibitor of
topoisomerase I (TOP1) and HIF1A, in Phase II testing to treat gastric and ovarian cancers and small cell lung cancer (SCLC). The compound is also in Phase Ib/IIa testing to treat renal cell carcinoma (RCC).

SciBX 6(15); doi:10.1038/scibx.2013.361
Published online April 18, 2013

Patent and licensing status unavailable

Hanna, S.C. et al. J. Clin. Invest.; published online April 8, 2013;
doi:10.1172/JCI66715
Contact: William Y. Kim, The University of North Carolina at Chapel Hill, Chapel Hill, N.C.
e-mail:

wykim@med.unc.edu